Virtual Meetings

Rise Nano Optics is a health technology company specializing in advanced nanotechnology lens solutions designed to selectively filter high-energy visible light wavelengths. Its patented SPECTRAGUARD™ technology integrates nanomaterial innovation, ophthalmic research, and scalable optical engineering to serve both clinical and consumer eyewear markets globally.

The Company has an established 50/50 joint venture partnership with GFL International Co., Ltd. to jointly advance exploration in Africa (the “LAF-GFL JV”) and through the LAF-GFL JV, the Company has an indirect 50% interest in a portfolio of exploration assets in hard rock pegmatite districts across a number of prospective African regions covering South Africa, Ivory Coast, Guinea, Mali, Morocco and Zimbabwe.

Financing: $0.40 unit w/ full wt @ $0.50

EraNova Metals is advancing the Adanac molybdenum project at its 100%-owned Ruby Creek property in British Columbia — a past construction-stage asset with prior feasibility, permitting, and over $40M in infrastructure already in place. The Company is moving toward a near-term PEA, with a clear path to feasibility, positioning it as one of the few scalable primary molybdenum development projects globally. At the same time, the broader Ruby Creek property hosts a district-scale system with high-grade gold, silver, copper, and tungsten targets emerging across the same land package. At a ~C$7M market cap, EraNova offers exposure to both near-term development catalysts and exploration upside that is not currently reflected in its valuation.

TempraMed Technologies Ltd. Is a global medical device company with a portfolio of innovative, temperature-controlled medication storage solutions. Founded with the mission to safeguard the effectiveness of life-saving medications, TempraMed develops patented, FDA-registered, thermal insulation devices that work 24/7 without batteries or external power. With a product line already in market including VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med, TempraMed enables patients and healthcare providers to confidently manage temperature-sensitive medications anywhere, anytime. With operations in North America, Europe, and Asia, TempraMed will continue to expand globally offering a solution for medication protection and adherence.

Voyageur Pharmaceuticals Ltd. (TSXV: VM, OTC Pink: VYYRF) is a Canadian radiology drug manufacturer of contrast media strategically positioned to resolve a global supply crisis in the diagnostic imaging sector. As the global contrast media market is projected to surge from US$6.77 billion in 2024 to US$13.86 billion by 2033, the industry has reached a critical breaking point where demand has outstripped supply to such an extent that the world’s top manufacturers are facing chronic shortages of both barium and iodine minerals. Voyageur addresses these vulnerabilities through its pioneering “From Earth to Bottle” vertical integration strategy. By leveraging its 100% interest in the Frances Creek project—home to high-purity barite, officially classified as a critical mineral—the company is bypassing fragile international dependencies to secure a reliable, domestic supply of Active Pharmaceutical Ingredients (API).

Atlas Salt is advancing the Great Atlantic Salt Project, North America’s largest undeveloped, high-grade, shallow deposit, targeting first production by 2030, as the continent’s first new salt mine in nearly 30 years. Located in Western Newfoundland, Canada with deep water port access, the Great Atlantic Salt Project aims to displace costly, high-emission salt imports in North America’s $2B+ surface de-icing market. With an approved Environmental Assessment, a recently-updated Feasibility Study (NPV8: $920M, $188M avg. annual after-tax FCF, 24-year life), strategic MOUs in place and an experienced development team, Atlas Salt is advancing towards securing project financing and commencing development.